Abstract
This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
